Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3349921rdf:typepubmed:Citationlld:pubmed
pubmed-article:3349921lifeskim:mentionsumls-concept:C0039142lld:lifeskim
pubmed-article:3349921lifeskim:mentionsumls-concept:C0004521lld:lifeskim
pubmed-article:3349921lifeskim:mentionsumls-concept:C0032582lld:lifeskim
pubmed-article:3349921lifeskim:mentionsumls-concept:C0055881lld:lifeskim
pubmed-article:3349921lifeskim:mentionsumls-concept:C0701852lld:lifeskim
pubmed-article:3349921lifeskim:mentionsumls-concept:C0733367lld:lifeskim
pubmed-article:3349921lifeskim:mentionsumls-concept:C0237519lld:lifeskim
pubmed-article:3349921lifeskim:mentionsumls-concept:C1706049lld:lifeskim
pubmed-article:3349921lifeskim:mentionsumls-concept:C0886812lld:lifeskim
pubmed-article:3349921pubmed:issue1lld:pubmed
pubmed-article:3349921pubmed:dateCreated1988-5-2lld:pubmed
pubmed-article:3349921pubmed:abstractTextThe stability and compatibility of clindamycin phosphate admixed with four beta-lactams, an experimental monobactam (aztreonam), and three cephalosporins (cefoperazone sodium, cefonicid sodium, and cefuroxime sodium), were studied. Aztreonam alone and the combination of clindamycin phosphate-aztreonam were prepared in duplicate polypropylene syringes. Each cephalosporin antibiotic as well as the three clindamycin phosphate-cephalosporin combinations were admixed in duplicate 100 ml partial-fill glass bottles containing either dextrose 5% in water or NaCl 0.9%. All solutions were examined, antibiotic concentrations were determined, and pH was measured at the time of admixture and 1, 4, 8, 12, 24, and 48 hours later. The solutions were maintained at room temperature under fluorescent lighting for the length of the study. Antibiotic concentrations were determined by drug-specific high performance liquid chromatographic assays. Significant instability or incompatibility was defined as a decrease in concentration of greater than ten percent relative to the initial concentration measured at the time of admixture. All antibiotics were stable for 48 hours. In the combination studies, clindamycin was stable for 48 hours, both in partial-fill glass bottles and syringes. Aztreonam, cefoperazone, cefonicid, and cefuroxime were also stable for 48 hours.lld:pubmed
pubmed-article:3349921pubmed:languageenglld:pubmed
pubmed-article:3349921pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:citationSubsetIMlld:pubmed
pubmed-article:3349921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3349921pubmed:statusMEDLINElld:pubmed
pubmed-article:3349921pubmed:monthJanlld:pubmed
pubmed-article:3349921pubmed:issn0012-6578lld:pubmed
pubmed-article:3349921pubmed:authorpubmed-author:BossoJ AJAlld:pubmed
pubmed-article:3349921pubmed:authorpubmed-author:TownsendR JRJlld:pubmed
pubmed-article:3349921pubmed:authorpubmed-author:MarbleD ADAlld:pubmed
pubmed-article:3349921pubmed:issnTypePrintlld:pubmed
pubmed-article:3349921pubmed:volume22lld:pubmed
pubmed-article:3349921pubmed:ownerNLMlld:pubmed
pubmed-article:3349921pubmed:authorsCompleteYlld:pubmed
pubmed-article:3349921pubmed:pagination54-7lld:pubmed
pubmed-article:3349921pubmed:dateRevised2000-12-18lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:meshHeadingpubmed-meshheading:3349921-...lld:pubmed
pubmed-article:3349921pubmed:year1988lld:pubmed
pubmed-article:3349921pubmed:articleTitleCompatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles.lld:pubmed
pubmed-article:3349921pubmed:affiliationDepartment of Internal Medicine, School of Medicine, University of Utah, Salt Lake City 84112.lld:pubmed
pubmed-article:3349921pubmed:publicationTypeJournal Articlelld:pubmed